Jim Dillon, president and CEO of Renal Guard, talks about the company’s decision to create Reprieve Cardiovascular, a start-up focusing on heart failure. Reprieve raised $7 million from outside investors, including Abiomed, and counts Serial Entrepreneur Howard Levin as chief medical officer.
Jim Dillon started at RenalGuard Solutions in 2017. He recently launched Reprieve Cardiovascular, a new affiliated company solely focused on developing a unique therapy for Acutely Decompensated Heart Failure patients. Previously he held a series of increasingly responsible corporate strategic and sales leadership positions at St. Jude Medical. Within these roles, he drove market development and new technology adoption, executed capital/consumable sales strategies and built high-performance elite commercial teams. Mr. Dillon was also involved with multiple highly successful medical device companies including startups VNUS Medical Technologies, Perclose, Heart Technologies, and Devices for Vascular Intervention as a key contributor to their acquisition and exit, as well as providing prominent leadership related to both sales and business development. Prior to joining St. Jude, he also held senior executive sales and marketing positions with such companies as Abiomed, TherOx, and InfraReDx, where he was intimately involved with global clinical development and commercial distribution.
Meet Our Host
A follower and fan of medtech for nearly two decades, Tom Salemi is the former bureau chief, venture capital, at Elsevier Business Intelligence, where he oversaw coverage of venture investments in medtech.